|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C19orf70 |
Gene summary for C19ORF70 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C19orf70 | Gene ID | 125988 |
| Gene name | mitochondrial contact site and cristae organizing system subunit 13 | |
| Gene Alias | C19orf70 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A140TA86 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 125988 | C19orf70 | C21 | Human | Oral cavity | OSCC | 1.19e-70 | 2.82e+00 | 0.2678 |
| 125988 | C19orf70 | C30 | Human | Oral cavity | OSCC | 6.17e-45 | 2.69e+00 | 0.3055 |
| 125988 | C19orf70 | C38 | Human | Oral cavity | OSCC | 5.18e-21 | 2.49e+00 | 0.172 |
| 125988 | C19orf70 | C43 | Human | Oral cavity | OSCC | 2.24e-79 | 1.68e+00 | 0.1704 |
| 125988 | C19orf70 | C46 | Human | Oral cavity | OSCC | 5.95e-33 | 1.09e+00 | 0.1673 |
| 125988 | C19orf70 | C51 | Human | Oral cavity | OSCC | 9.26e-36 | 1.99e+00 | 0.2674 |
| 125988 | C19orf70 | C57 | Human | Oral cavity | OSCC | 4.45e-23 | 1.21e+00 | 0.1679 |
| 125988 | C19orf70 | C06 | Human | Oral cavity | OSCC | 1.20e-13 | 1.99e+00 | 0.2699 |
| 125988 | C19orf70 | C07 | Human | Oral cavity | OSCC | 4.00e-17 | 2.17e+00 | 0.2491 |
| 125988 | C19orf70 | C08 | Human | Oral cavity | OSCC | 5.58e-90 | 1.80e+00 | 0.1919 |
| 125988 | C19orf70 | C09 | Human | Oral cavity | OSCC | 5.67e-42 | 1.32e+00 | 0.1431 |
| 125988 | C19orf70 | LN22 | Human | Oral cavity | OSCC | 1.30e-09 | 1.68e+00 | 0.1733 |
| 125988 | C19orf70 | LN38 | Human | Oral cavity | OSCC | 8.38e-13 | 2.12e+00 | 0.168 |
| 125988 | C19orf70 | LN46 | Human | Oral cavity | OSCC | 1.68e-22 | 1.19e+00 | 0.1666 |
| 125988 | C19orf70 | LP15 | Human | Oral cavity | LP | 6.14e-11 | 2.04e+00 | 0.2174 |
| 125988 | C19orf70 | LP17 | Human | Oral cavity | LP | 5.21e-12 | 1.78e+00 | 0.2349 |
| 125988 | C19orf70 | EOLP-1 | Human | Oral cavity | EOLP | 3.95e-11 | -2.79e-01 | -0.0202 |
| 125988 | C19orf70 | EOLP-2 | Human | Oral cavity | EOLP | 9.25e-09 | -2.79e-01 | -0.0203 |
| 125988 | C19orf70 | NEOLP-1 | Human | Oral cavity | NEOLP | 9.03e-10 | -2.79e-01 | -0.0194 |
| 125988 | C19orf70 | NEOLP-2 | Human | Oral cavity | NEOLP | 1.90e-10 | -2.79e-01 | -0.0196 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C19orf70 | SNV | Missense_Mutation | novel | c.333N>A | p.Met111Ile | p.M111I | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| C19orf70 | SNV | Missense_Mutation | rs767797342 | c.274N>G | p.Leu92Val | p.L92V | protein_coding | tolerated(0.1) | benign(0.172) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C19orf70 | SNV | Missense_Mutation | novel | c.370G>A | p.Ala124Thr | p.A124T | protein_coding | tolerated(0.13) | probably_damaging(0.918) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C19orf70 | SNV | Missense_Mutation | novel | c.291G>T | p.Lys97Asn | p.K97N | protein_coding | tolerated(0.08) | possibly_damaging(0.772) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C19orf70 | deletion | Frame_Shift_Del | novel | c.363delN | p.Ser122ProfsTer14 | p.S122Pfs*14 | protein_coding | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| C19orf70 | deletion | Frame_Shift_Del | rs751944867 | c.216delN | p.Ala73ProfsTer39 | p.A73Pfs*39 | protein_coding | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
| C19orf70 | SNV | Missense_Mutation | rs773529324 | c.308G>A | p.Arg103His | p.R103H | protein_coding | tolerated(0.48) | benign(0.062) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C19orf70 | SNV | Missense_Mutation | rs773529324 | c.308G>A | p.Arg103His | p.R103H | protein_coding | tolerated(0.48) | benign(0.062) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C19orf70 | SNV | Missense_Mutation | c.307N>A | p.Arg103Ser | p.R103S | protein_coding | tolerated(0.72) | possibly_damaging(0.822) | TCGA-BG-A18B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| C19orf70 | SNV | Missense_Mutation | novel | c.241N>A | p.Val81Met | p.V81M | protein_coding | tolerated(0.07) | possibly_damaging(0.868) | TCGA-D1-A161-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |